Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Metz

Showing results (231-240 of 258) with videos related to

Pageof 26
Sort By:
Nature Medicine|November 9, 2021
Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trialMartin Metz, Gordon Sussman, Rémi Gagnon, et al.
Allergy|November 13, 2021
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension studyMarcus Maurer, Ana Giménez-Arnau, Jonathan A Bernstein, et al.
Allergy, Asthma & Immunology Research|July 2, 2021
Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous UrticariaPavel Kolkhir, Sabine Altrichter, Riccardo Asero, et al.
The Journal of Dermatological Treatment|March 11, 2026
Dupilumab subgroup responder analysis: a <i>post hoc</i> analysis from LIBERTY PRIME and PRIME2 in prurigo nodularisBrian S Kim, Shawn G Kwatra, Gil Yosipovitch, et al.
Nature Medicine|April 1, 2008
Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsisAdrian M Piliponsky, Ching-Cheng Chen, Toshihiko Nishimura, et al.
International Archives of Allergy and Immunology|April 1, 2020
Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020Marcus Maurer, Kilian Eyerich, Stefanie Eyerich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 22, 2023
Chronic prurigo: Insufficient disease control in spite of high healthcare usageManuel P Pereira, Elke Weisshaar, Jon Anders Halvorsen, et al.
The Journal of Allergy and Clinical Immunology|October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studiesAna Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trialsAna Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
The Journal of Allergy and Clinical Immunology|July 6, 2024
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonistsJoshua Wollam, Michelle Solomon, Christiane Villescaz, et al.
Pageof 26

Showing results (231-240 of 258) with videos related to

Sort By:
Pageof 26
Nature Medicine|November 9, 2021
Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trialMartin Metz, Gordon Sussman, Rémi Gagnon, et al.
Allergy|November 13, 2021
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension studyMarcus Maurer, Ana Giménez-Arnau, Jonathan A Bernstein, et al.
Allergy, Asthma & Immunology Research|July 2, 2021
Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous UrticariaPavel Kolkhir, Sabine Altrichter, Riccardo Asero, et al.
The Journal of Dermatological Treatment|March 11, 2026
Dupilumab subgroup responder analysis: a <i>post hoc</i> analysis from LIBERTY PRIME and PRIME2 in prurigo nodularisBrian S Kim, Shawn G Kwatra, Gil Yosipovitch, et al.
Nature Medicine|April 1, 2008
Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsisAdrian M Piliponsky, Ching-Cheng Chen, Toshihiko Nishimura, et al.
International Archives of Allergy and Immunology|April 1, 2020
Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020Marcus Maurer, Kilian Eyerich, Stefanie Eyerich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 22, 2023
Chronic prurigo: Insufficient disease control in spite of high healthcare usageManuel P Pereira, Elke Weisshaar, Jon Anders Halvorsen, et al.
The Journal of Allergy and Clinical Immunology|October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studiesAna Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trialsAna Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
The Journal of Allergy and Clinical Immunology|July 6, 2024
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonistsJoshua Wollam, Michelle Solomon, Christiane Villescaz, et al.
Pageof 26